Dominari Holdings Inc. (DOMH) operates as a Nasdaq-listed holding company in wealth management, investment banking, sales and trading, asset management, and insurance through subsidiaries including Dominari Financial and Dominari Securities. With essentially no active sell-side coverage, the analyst-consensus approach is not available. The $16.00 figure that appears on some sites traces back to the prior AIkido Pharma period and does not reflect current research. MarketBeat shows only a single Sell rating from Weiss Ratings in October 2026, without an accompanying price target.
That leaves the $2.50 level as a publicly discussed reference rather than a formal consensus. TipRanks’ AI-driven analysis points to $2.50, and the figure sits just above the $2.20 reduced exercise price offered to Series A warrant holders in August 2026. These publicly noted levels anchor the discussion that follows.
In early November 2026, DOMH changed hands near $1.40–$1.65, well below its 52-week high above $8.00. Using roughly $1.60 as a starting point, a move to $2.50 would represent upside of about 55%–60%. Nothing guarantees that distance will be covered.
Full-year 2025 revenue rose roughly 487% to about $123.1 million, driven by underwriting activity. In the first half of 2026, revenue advanced another 14% to $52.6 million, and the second-quarter operating loss narrowed to $1.1 million from $14.9 million a year earlier. Even so, the company recorded a net loss attributable to common stockholders of $5.4 million in the second quarter, and the P/E ratio remains negative.
DOMH has followed a broad downtrend from its 52-week high above $8.00. The $2.20 reduced warrant exercise price serves as a nearby structural reference, while $2.50 represents a round-number resistance zone that would need to be cleared and held. Recent lows near $1.40–$1.60 act as approximate support, though thin trading and wide daily ranges make precise levels harder to define.
Without an active analyst target to anchor a 12-month horizon, attention naturally turns to the next earnings release and any accompanying guidance, progress on the remaining share buyback, further warrant activity, and new deal-flow announcements from Dominari Securities. Broader capital-markets conditions, including IPO activity, interest rates, and investor risk appetite, also matter directly to the investment-banking business. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a thinly traded, volatile name like DOMH, these signals can help surface opportunities and track trend changes more efficiently than manual review alone.
Reaching the $2.50 level would require a substantial advance of roughly 55%–60% from recent prices. Dominari Holdings (DOMH) shows clear momentum through revenue growth, a narrowing operating loss, a profitable financial-services segment, dividends, and an active buyback. At the same time, ongoing net losses, warrant dilution, extreme volatility, and minimal analyst coverage remain material considerations. The outcome depends on sustained deal flow, conversion of recurring revenue into consistent profits, and prudent capital-structure management. No forecast is offered here; investors should track earnings, buyback execution, warrant developments, and capital-markets conditions before forming conclusions.
I regularly turn to Tickeron’s AI Screener and AI Daily Buy/Sell Signals when evaluating micro-cap names like this one. These tools help me quickly compare peers, spot pattern changes, and review signal history alongside the fundamentals discussed above, giving a more complete picture before deciding on next steps.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
DOMH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOMH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for DOMH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.554) is normal, around the industry mean (3.120). P/E Ratio (-0.412) is within average values for comparable stocks, (6.734). Projected Growth (PEG Ratio) (0.050) is also within normal values, averaging (0.809). Dividend Yield (0.886) settles around the average of (8.976) among similar stocks. P/S Ratio (0.303) is also within normal values, averaging (16.899).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. DOMH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOMH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biotechnology development company, which engages in the provision of diversified commercialization platform for protected technologies
Industry InvestmentBanksBrokers